clarithromycin has been researched along with Blood Poisoning in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Castelletti, S; Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, E; Kamysz, W; Orlando, F; Riva, A; Rocchi, M; Saba, V; Scalise, G; Silvestri, C | 1 |
| Anisoglou, S; Antoniadou, A; Antoniadou, E; Chaloulis, P; Dauby, N; De Bels, D; Floros, I; Frantzeskaki, F; Giamarellos-Bourboulis, EJ; Grimaldi, D; Karageorgos, A; Karakike, E; Karampela, N; Lada, M; Massa, E; Mitrou, I; Mouloudi, E; Pappa, E; Patrani, M; Pitsoulis, A; Psaroulis, K; Roger, T; Roumpoutsou, M; Schrijver, IT; Scicluna, BP; Tsangaris, I; Vlachogianni, G; Wiersinga, WJ | 1 |
| Arulkumaran, N; Cesar, A; Singer, M; Snow, TAC | 1 |
| Antonopoulou, A; Armaganidis, A; Baziaka, F; Douzinas, EE; Georgopoulou, AP; Giamarellos-Bourboulis, EJ; Gogos, C; Kanni, T; Kopterides, P; Koratzanis, G; Kotsaki, A; Koutelidakis, I; Koutoukas, P; Ladas, M; Lymberopoulou, K; Maniatis, N; Marioli, A; Mouktaroudi, M; Mylona, V; Papadomichelakis, E; Papageorgiou, C; Papaziogas, B; Pelekanos, N; Pelekanou, A; Raftogiannis, M; Savva, A; Spyridaki, A; Tsaganos, T; Tsangaris, I; Vaki, I | 1 |
| Antony, SJ | 1 |
| Armaganidis, A; Christodoulou, S; Giamarellos-Bourboulis, EJ; Kotanidou, A; Papadomichelakis, E; Pratikaki, M; Raftogiannis, M; Routsi, C; Tsaganos, T | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Karagianni, V; Kotanidou, A; Koutoukas, P; Mouktaroudi, M; Netea, MG; Orfanos, SE; Pelekanou, A; Raftogiannis, M; Routsi, C; Spyridaki, A; Tsaganos, T; van der Meer, JW | 1 |
| Cadeo, B; Colombini, P; Cristini, F; Matteeli, A; Signorini, L; Simeone, F; Tonegatti, L; Viale, P | 1 |
| Adamis, T; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Laoutaris, G; Mouktaroudi, M; Perrea, D; Sabracos, L | 1 |
| Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kousoulas, V; Koutoukas, P; Panagou, C; Perrea, D; Sabracos, L | 1 |
| Adamis, T; Baziaka, F; Giamarellos-Bourboulis, E; Giamarellou, H; Karayannacos, P; Koutoukas, P; Plachouras, D; Raftogiannis, M; Sabracos, L; Tsaganos, T | 1 |
| Adamis, T; Baziaka, F; Chrisofos, M; Douzinas, EE; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Raftogiannis, M; Sabracos, L; Tziortzioti, V | 1 |
| Antonopoulou, A; Armaganidis, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kollias, S; Koronaios, A; Kotanidou, A; Koussoulas, V; Koutoukas, P; Markaki, V; Papadomichelakis, E; Pechère, JC; Plachouras, D; Raftogiannis, M; Roussos, C; Routsi, C; Tsaganos, T; Zervakis, D | 1 |
| Brown, BA; Wallace, RJ | 1 |
| Bodey, GP; Ho, DH; LeBlanc, B; Rolston, KV | 1 |
| Bailer, R; Fernandes, PB; Gade, E; Hardy, D; McDonald, E; Pintar, J; Ramer, N; Swanson, R | 1 |
1 review(s) available for clarithromycin and Blood Poisoning
| Article | Year |
|---|---|
Macrocycle molecules for the management of systemic infections: the clarithromycin paradigm.
Topics: Anti-Bacterial Agents; Clarithromycin; Humans; Macrolides; Pneumonia; Retrospective Studies; Sepsis; Systemic Inflammatory Response Syndrome | 2010 |
5 trial(s) available for clarithromycin and Blood Poisoning
| Article | Year |
|---|---|
Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial.
Topics: Administration, Intravenous; Clarithromycin; Humans; Multiple Organ Failure; Oxygen; Sepsis | 2022 |
Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Health Care Costs; Humans; Male; Middle Aged; Placebos; Prospective Studies; Sepsis; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis.
Topics: Administration, Intravenous; Adult; Anti-Infective Agents; Clarithromycin; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Schedule; Female; Greece; Hospitalization; Humans; Intensive Care Units; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Sepsis; Survival Analysis; Survivors | 2016 |
Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study.
Topics: Apoptosis; B7-2 Antigen; CD40 Ligand; Clarithromycin; Double-Blind Method; Gram-Negative Bacteria; Humans; Interleukin-10; Interleukin-6; Pneumonia, Ventilator-Associated; Sepsis; Tumor Necrosis Factor-alpha | 2012 |
Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Sepsis; Treatment Outcome | 2008 |
11 other study(ies) available for clarithromycin and Blood Poisoning
| Article | Year |
|---|---|
Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Clarithromycin; Disease Models, Animal; DNA-Binding Proteins; Drug Therapy, Combination; Endotoxins; Escherichia coli; Escherichia coli Infections; Humans; Male; Peptides, Cyclic; Rats; Rats, Wistar; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Clarithromycin as an immunomodulator in sepsis: still a (IN)CLASS act.
Topics: Anti-Bacterial Agents; Clarithromycin; Humans; Immunologic Factors; Multiple Organ Failure; Sepsis | 2022 |
Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host.
Topics: Adult; Catheter-Related Infections; Ciprofloxacin; Clarithromycin; Cross Infection; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ovarian Neoplasms; Sepsis; Vascular Access Devices | 2015 |
Co-infection with Esptein-Barr virus and Bartonella henselae resulting in systemic bartonellosis.
Topics: Animals; Bartonella henselae; Cat-Scratch Disease; Cats; Child; Clarithromycin; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunoglobulin G; Immunoglobulin M; Rifampin; Sepsis; Serologic Tests | 2002 |
Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
Topics: Acute Disease; Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Immunity; Lipopolysaccharides; Male; Malondialdehyde; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Sepsis; Survival Analysis; Tumor Necrosis Factor-alpha | 2004 |
Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Inflammation; Lipopolysaccharides; Malondialdehyde; Pyelonephritis; Rabbits; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2005 |
Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli.
Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Caspase 3; Caspases; Clarithromycin; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Immunologic Factors; Male; Malondialdehyde; Pulmonary Edema; Pyelonephritis; Rabbits; Sepsis; Tumor Necrosis Factor-alpha | 2005 |
Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Humans; Immunologic Factors; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Sepsis | 2008 |
Catheter sepsis due to Mycobacterium chelonae.
Topics: Anti-Bacterial Agents; Catheterization; Clarithromycin; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Sepsis | 1998 |
Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
Topics: Anti-Bacterial Agents; Clarithromycin; Clindamycin; Erythromycin; Gram-Positive Bacteria; Humans; Macrolides; Microbial Sensitivity Tests; Neoplasms; Roxithromycin; Sepsis | 1990 |
Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Culture Media; Erythromycin; Female; Haemophilus Infections; Haemophilus influenzae; Kinetics; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Sepsis | 1987 |